BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24562809)

  • 21. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel and naringenin-loaded solid lipid nanoparticles surface modified with cyclic peptides with improved tumor targeting ability in glioblastoma multiforme.
    Wang L; Wang X; Shen L; Alrobaian M; Panda SK; Almasmoum HA; Ghaith MM; Almaimani RA; Ibrahim IAA; Singh T; Baothman AA; Choudhry H; Beg S
    Biomed Pharmacother; 2021 Jun; 138():111461. PubMed ID: 33706131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles.
    Jang DJ; Moon C; Oh E
    Biomed Pharmacother; 2016 May; 80():162-172. PubMed ID: 27133053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations.
    Ramalingam P; Ko YT
    Pharm Res; 2015 Feb; 32(2):389-402. PubMed ID: 25082210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles.
    Jia Y; Ji J; Wang F; Shi L; Yu J; Wang D
    Drug Deliv; 2016 May; 23(4):1317-25. PubMed ID: 25371296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation, Characterization, and Evaluation of Eudragit-Coated Saxagliptin Nanoparticles Using 3 Factorial Design Modules.
    Alhamhoom Y; Ravi G; Osmani RAM; Hani U; Prakash GM
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364338
    [No Abstract]   [Full Text] [Related]  

  • 28. Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles.
    Kumar M; Sharma G; Singla D; Singh S; Kakkar V; Gulati JS; Kaur IP
    Pharm Nanotechnol; 2020; 8(6):495-510. PubMed ID: 33115399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced in vitro cytotoxicity and anti-tumor activity of vorinostat-loaded pluronic micelles with prolonged release and reduced hepatic and renal toxicities.
    Mohamed EA; Abu Hashim II; Yusif RM; Suddek GM; Shaaban AAA; Badria FAE
    Eur J Pharm Sci; 2017 Jan; 96():232-242. PubMed ID: 27667706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
    Baek JS; Cho CW
    J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery.
    Fang YP; Wu PC; Huang YB; Tzeng CC; Chen YL; Hung YH; Tsai MJ; Tsai YH
    Int J Nanomedicine; 2012; 7():4995-5005. PubMed ID: 23055719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic.
    Tran TH; Chu DT; Truong DH; Tak JW; Jeong JH; Hoang VL; Yong CS; Kim JO
    Drug Deliv; 2016 May; 23(4):1335-43. PubMed ID: 25547270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained release of piroxicam from solid lipid nanoparticle as an effective anti-inflammatory therapeutics in vivo.
    Peng LH; Wei W; Shan YH; Chong YS; Yu L; Gao JQ
    Drug Dev Ind Pharm; 2017 Jan; 43(1):55-66. PubMed ID: 27498809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles.
    Wang W; Zhu R; Xie Q; Li A; Xiao Y; Li K; Liu H; Cui D; Chen Y; Wang S
    Int J Nanomedicine; 2012; 7():3667-77. PubMed ID: 22888226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
    Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
    Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles.
    Varshosaz J; Minayian M; Moazen E
    J Liposome Res; 2010 Jun; 20(2):115-23. PubMed ID: 19694503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.
    Xue M; Yang MX; Zhang W; Li XM; Gao DH; Ou ZM; Li ZP; Liu SH; Li XJ; Yang SY
    Int J Nanomedicine; 2013; 8():4677-87. PubMed ID: 24353417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: potential tool for the treatment of androgenic alopecia.
    Hamishehkar H; Ghanbarzadeh S; Sepehran S; Javadzadeh Y; Adib ZM; Kouhsoltani M
    Drug Dev Ind Pharm; 2016; 42(6):846-53. PubMed ID: 26154267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.